PDS Biotechnology Corporation

NASDAQ:PDSB

Biotechnology

Healthcare
$0.92 +1.21%

+$0.01 today

Market cap
$51.58M
Beta
1.56
P/E (TTM)
-1.5
EPS (TTM)
-$0.60
52W Low $0.51High $1.67

Volume 5.25M

Average 1.04M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$27.75B

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$12.77B

FY 2025 · Annual

+63176.2% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(16.92M)(40.85M)(42.94M)(37.61M)(34.5B)
Depreciation & Amortization5.36K8617.36K21.11K1.55B
Deferred Income Tax00000
Stock-Based Compensation4.11M5.2M7.61M6.85M4.11B
Change in Working Capital75.82K4.47M(199.28K)(5.75M)(382.97K)
Accounts Receivables00000
Inventory00000
Accounts Payables(105.82K)(90.12K)5.76M(5.3M)1.89M
Other Working Capital181.64K4.57M(5.96M)(453.77K)(2.27M)
Other Non-Cash Items241.03K5.47M1.87M1.46M1.08B
Operating Cash Flow(12.49M)(25.71M)(33.64M)(35.03M)(27.75B)
Capital Expenditures000(29K)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow000(29K)0
Debt Repayment025M(59.3K)(3.18M)(7.56M)
Common Stock Issued48.54M9.86M16.13M22.6M20.34M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities344.13K(568.87K)308.94K774.09K12.76B
Financing Cash Flow48.89M34.29M16.38M20.19M12.77B
Effect of Forex Changes00000
Net Change in Cash36.4M8.58M(17.26M)(14.87M)(14.98B)
Free Cash Flow(12.49M)(25.71M)(33.64M)(35.06M)(27.75B)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$34.5B
+ D&A$1.6B
+ Stock-Based Comp$4.1B
+ Deferred Tax$0
- Working Capital-$383.0K
+ Other Non-Cash$1.1B
= Operating Cash Flow-$27.8B
- Capex$0
= Free Cash Flow-$27.8B

Analysis

FY2025 free cash flow is -$27.8B. FCF conversion is 80.5% of net income. Operating cash flow was -$27.8B, with capex of $0. The largest bridge item is Stock-Based Comp at $4.1B.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 21, 2026
8-KCurrent reportOct 21, 2026
3Initial statement of beneficial ownershipOct 21, 2026
3Initial statement of beneficial ownershipOct 20, 2026
4Statement of changes in beneficial ownershipOct 20, 2026

Does PDSB generate free cash flow?

PDS Biotechnology Corporation (PDSB) generated -$27.75B of free cash flow in fiscal 2025.

How much operating cash flow does PDSB produce?

Operating cash flow was -$27.75B, before capital expenditures of $0.00.